European Journal Of Clinical Pharmacology

Journal Title：European Journal Of Clinical Pharmacology

The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed.

Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.

Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves

-a compound that is interesting and new in some basic or fundamental way, or

-methods that are original in some basic sense, or

-a highly unexpected outcome, or

-conclusions that are scientifically novel in some basic or fundamental sense.

《欧洲临床药理学杂志》发表关于人类临床药理学和药物治疗各个方面的原创论文。欢迎投稿，主题包括：治疗试验、药代动力学/药效学、药物遗传学、药物代谢、药物不良反应、药物相互作用、药物开发的各个方面、与临床药理学教学相关的发展、药物流行病学以及与合理处方和安全用药相关的事项。也欢迎与这些主题相关的方法学贡献。

动物实验数据仅在同一篇论文中报告的人类原始数据背景下才被接受。EJCP 仅会考虑描述不同人群等位基因变异频率的稿件，前提是这些信息与功能数据或新的有趣变异相关。频率高度相关的差异，对相应人群的药物治疗有重大影响，可以以致编辑信的形式提交。

作为新药开发的一部分，简单的 I 期药代动力学或药效学研究仅在论文涉及以下方面时才会被考虑发表：

- 某种化合物在某些基本或根本方面有趣且新颖，或

- 某种方法在某些基本意义上是原创的，或

- 非常出乎意料的结果，或

- 结论在某些基本或根本意义上具有科学上的新颖性。

European Journal Of Clinical Pharmacology创刊于1968年，由Springer Berlin Heidelberg出版商出版，收稿方向涵盖医学 - 药学全领域，此刊是中等级别的SCI期刊，所以过审相对来讲不是特别难，但是该刊专业认可度不错，仍然是一本值得选择的SCI期刊 。平均审稿速度 一般,3-8周 ，影响因子指数2.4，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。